Eric Mou

Clinical Assistant Professor

University of Iowa Hospitals and Clinics

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Eric Mou is a Clinical Assistant Professor at the University of Iowa Hospitals and Clinics in the United States. His research primarily focuses on lymphoma treatment and prediction models, particularly in Hodgkin lymphoma and cutaneous T-cell lymphomas. Recent articles authored by Dr. Mou highlight advancements in novel therapies and risk stratification in hematological malignancies.

Articles (19)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

FRANCE

View details

UNITED STATES

View details

Julia Klesney-Tait

The University of Iowa Roy J and Lucille A Carver College of Medicine

UNITED STATES

View details

Vincent Liu

UNITED STATES

View details

Ali Jabbari

Associate Professor

Iowa State University

UNITED STATES

View details

Youn H. Kim

Stanford University

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Eric Mou

Research Interests

Explore related searches

Contact this professor

About

Articles (19)

The A-HIPI prediction model in advanced-stage Hodgkin lymphoma: identification of risk groups and creation of an online tool

Subcutaneous panniculitis-like T-cell lymphoma complicated by severe hemophagocytic syndrome with dramatic response to pralatrexate: a case report

Incorporating novel therapies into the treatment of older patients with classic Hodgkin lymphoma.

An Individualized Prediction Model for Early-Stage Classic Hodgkin's Lymphoma.

Sezary syndrome initially presenting as pityriasis rubra pilaris: Clinicopathologic study of 3 cases

Overcoming Tagraxofusp-Erzs Monotherapy Resistance in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) in a Real-World Clinical Setting

Chimeric Antigen Receptor T-Cell Therapy for Refractory Post-transplant Lymphoproliferative Disorder after Lung Transplantation

Clinical characteristics, treatment patterns, and outcomes of cytotoxic cutaneous T‐cell lymphomas

Molecular techniques drive cutting edge advancements in management of cutaneous T cell lymphoma.

Increasing tissue requirements in lymphoma trials may exclude patients with high-risk disease or worse prognosis

The Advanced-Stage Hodgkin Lymphoma International Prognostic Index: Development and Validation of a Clinical Prediction Model From the HoLISTIC Consortium.

Integrating Novel Agents into the Treatment of Advanced Mycosis Fungoides and Sézary Syndrome.

Sequential Pembrolizumab and AVD is Highly Effective at any PD-L1 Expression Level in Untreated Hodgkin Lymphoma

Impact of initial biopsy type on the time to final diagnostic biopsy in patients with follicular lymphoma and suspected histologic transformation.

Multicenter analysis of geriatric fitness and real-world outcomes in older patients with classical Hodgkin lymphoma

Global Cytopathology-Hematopathology Practice Trends.

A randomized study of a best practice alert for platelet transfusions

Long-Term Outcomes of Patients With Early Stage Nonbulky Hodgkin Lymphoma Treated With Combined Modality Therapy in the Stanford V Trials (the G4 and G5 Studies)

Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma.

Collaborators (13)

Matthew Maurer

Joshua Menke

Umar Farooq

James Cerhan

Andrea Gallamini

Michael S. Khodadoust

Natalie Grover

Eliza Hawkes

Ron Balassanian

Julia Klesney-Tait

Vincent Liu

Ali Jabbari

Youn H. Kim

Make your next move.